CME in Minutes: Education in Dermatology

• Sheilagh M. Maguiness, MD, FAAP / Elizabeth Vainder, MD, FAAP - Escalating Atopic Dermatitis Treatment in Pediatric Patients With Confidence: What Do the Guidelines Tell Us?

  Please visit answersincme.com/RTS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, a pediatrician and a pediatric dermatologist discuss strategies for optimizing biologic treatment for moderate to severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when treatment escalation to systemic therapy is warranted in pediatric patients with atopic dermatitis (AD); Select the optimal biologic for a given pediatric patient with moderate to severe AD; and Outline strategies to optimize biologic treatment in pediatric patients with moderate to severe AD. This activity is intended for US healthcare professionals only.

  --------  

  18:49

  --------

  18:49
• Tina Bhutani, MD, MAS, FAAD / Robin K. Dore, MD - The Dermatology-Rheumatology Psoriatic Playbook: Advancing Care With Novel Oral Therapies in the Evolving PsA Landscape

  Please visit answersincme.com/860/99534447-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.

  --------  

  1:01:30

  --------

  1:01:30
• April W. Armstrong, MD, MPH / Linda Stein Gold, MD / Clive M. Liu, MD - Personalizing Psoriasis Care Across the Map: Navigating Regional Barriers to Integrating Oral Small Molecule Treatment for Moderate to Severe Disease

  Please visit answersincme.com/860/99505211-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in psoriasis discuss real‑world strategies for using oral small molecules in moderate to severe disease. Upon completion of this activity, participants should be better able to: Identify patients with moderate to severe plaque psoriasis who would benefit from oral small molecule therapy; Differentiate the targets/mechanisms of action of available oral small molecule therapy for moderate to severe plaque psoriasis; and Integrate strategies to individualize oral small molecule therapy for moderate to severe plaque psoriasis, while balancing safety, considering regional barriers.

  --------  

  1:04:30

  --------

  1:04:30
• Michael Postow, MD - Enhancing First-Line Treatment Selection in Advanced Melanoma: A Patient-Centered Approach

  Please visit answersincme.com/GVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of melanoma discusses the clinical evidence for guideline-preferred first-line treatment options and factors informing treatment in metastatic or unresectable disease. Upon completion of this activity, participants should be better able to: Summarize efficacy and safety evidence on the guideline-preferred first-line therapies for metastatic or unresectable melanoma; and Review factors informing treatment selection among the guideline-preferred first-line therapies for patients with metastatic or unresectable melanoma.

  --------  

  17:07

  --------

  17:07
• Terry Faleye, MPAS, PA-C / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Beyond Biologics for Psoriasis and PsA: TYK2 Inhibitors and Practical Considerations for Personalizing Care

  Please visit answersincme.com/860/100752367-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of psoriatic disease discuss challenges in treatment, emerging TYK2 inhibitor therapies, and evidence-based strategies to optimize patient care. Upon completion of this activity, participants should be better able to: Recognize how nurse practitioners and physician associates can help address barriers to care and enhance outcomes for patients with moderate to severe plaque psoriasis; Differentiate TYK2 signaling from JAK pathways and explain the relevance of these distinctions in clinical outcomes; Evaluate the impact of emerging data on TYK2 inhibitors in shaping therapeutic strategies for psoriatic disease; and Apply strategies for aligning TYK2 inhibitor therapy with patient needs and multidisciplinary care plans.

  --------  

  1:14:45

  --------

  1:14:45

More Health & Wellness podcasts

Trending Health & Wellness podcasts

About CME in Minutes: Education in Dermatology

CME in Minutes: Education in Dermatology: Podcasts in Family